OQROStart free trial
Politician trade (House)

Amgen (AMGN): Rep. Marjorie Taylor Greene (GA14) disclosed a purchase $1K–$15K

Rep. Marjorie Taylor Greene (GA14) disclosed a purchase of Amgen in the $1K–$15K range.

$1,001–$15,000
Reported range · official band, not an exact amount
5 days
Disclosure lag
Traded
May 14, 2025
Disclosed
May 19, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Aug 7, 2024CongressDisclosed purchase of AMGN — reported range $1,001 - $15,000
  2. Feb 11, 2025CongressDisclosed sale of AMGN — reported range $1,001 - $15,000
  3. Apr 7, 2025FDAFDA drug approval: Amjevita
  4. Apr 8, 2025CongressDisclosed sale of AMGN — reported range $1,001 - $15,000
  5. Apr 11, 2025CongressDisclosed purchase of AMGN — reported range $15,001 - $50,000
  6. Apr 15, 2025CongressDisclosed sale of AMGN — reported range $15,001 - $50,000
  7. Apr 16, 2025Congress · 1 personMembers of Congress: 2 purchases
  8. May 2, 2025InsiderOfficer sold ~$280K of AMGN shares in the open market
  9. May 5, 2025CongressDisclosed purchase of AMGN — reported range $1,001 - $15,000
  10. May 12, 2025CongressDisclosed sale of AMGN — reported range $15,001 - $50,000
  11. May 14, 2025 · this disclosureCongressDisclosed purchase of AMGN — reported range $1,001 - $15,000

What came next

  1. May 20, 2025FDAFDA drug approval: Amjevita
  2. May 22, 2025FDAFDA drug approval: Prolia
  3. Jun 5, 2025InsiderOfficer sold ~$435K of AMGN shares in the open market
  4. Jun 6, 2025CongressDisclosed purchase of AMGN — reported range $1,001 - $15,000
  5. Jun 24, 2025CongressDisclosed purchase of AMGN — reported range $1,001 - $15,000
  6. Jul 23, 2025FDAFDA drug approval: Otezla
  7. Aug 20, 2025InsiderOfficer sold ~$376K of AMGN shares in the open market
  8. Aug 29, 2025FDAFDA drug approval: Otezla
  9. Aug 29, 2025FDAFDA drug approval: Otezla
  10. Sep 8, 20255% stakeThe Vanguard Group reported a passive stake (13G) of 10.0%
View the official recordHouse Clerk periodic transaction report

How to read House Clerk periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Amgen

For Amgen, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports and 54 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its AMGN page.

Other recent filings by Rep. Marjorie Taylor Greene (GA14)

The full history of Rep. Marjorie Taylor Greene (GA14) is on the profile page.

How this filing works

Explore the data

Other disclosures at Amgen

Everything OQRO holds on this company is on its AMGN page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Start free trialAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data